Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Kyuho Kim  (Kim K) 7 Articles
Others
Glucose Regulation after Partial Pancreatectomy: A Comparison of Pancreaticoduodenectomy and Distal Pancreatectomy in the Short and Long Term
Jun Suh Lee, Minji Sohn, Kyuho Kim, Yoo-Seok Yoon, Soo Lim
Diabetes Metab J. 2023;47(5):703-714.   Published online June 22, 2023
DOI: https://doi.org/10.4093/dmj.2022.0205
  • 1,567 View
  • 148 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Long term quality of life is becoming increasingly crucial as survival following partial pancreatectomy rises. The purpose of this study was to investigate the difference in glucose dysregulation after pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
Methods
In this prospective observational study from 2015 to 2018, 224 patients who underwent partial pancreatectomy were selected: 152 (67.9%) received PD and 72 (32.1%) received DP. Comprehensive assessment for glucose regulation, including a 75 g oral glucose tolerance test was conducted preoperatively, and 1, 12, and 52 weeks after surgery. Patients were further monitored up to 3 years to investigate development of new-onset diabetes mellitus (NODM) in patients without diabetes mellitus (DM) at baseline or worsening of glucose regulation (≥1% increase in glycosylated hemoglobin [HbA1c]) in those with preexisting DM.
Results
The disposition index, an integrated measure of β-cell function, decreased 1 week after surgery in both groups, but it increased more than baseline level in the PD group while its decreased level was maintained in the DP group, resulting in a between-group difference at the 1-year examination (P<0.001). During follow-up, the DP group showed higher incidence of NODM and worsening of glucose regulation than the PD group with hazard ratio (HR) 4.29 (95% confidence interval [CI], 1.49 to 12.3) and HR 2.15 (95% CI, 1.09 to 4.24), respectively, in the multivariate analysis including dynamic glycemic excursion profile. In the DP procedure, distal DP and spleen preservation were associated with better glucose regulation. DP had a stronger association with glucose dysregulation than PD.
Conclusion
Proactive surveillance of glucose dysregulation is advised, particularly for patients who receive DP.
Guideline/Fact Sheet
Diabetes Mellitus in the Elderly Adults in Korea: Based on Data from the Korea National Health and Nutrition Examination Survey 2019 to 2020
Seung-Hyun Ko, Kyung Do Han, Yong-Moon Park, Jae-Seung Yun, Kyuho Kim, Jae-Hyun Bae, Hyuk-Sang Kwon, Nan-Hee Kim
Diabetes Metab J. 2023;47(5):643-652.   Published online August 7, 2023
DOI: https://doi.org/10.4093/dmj.2023.0041
  • 2,125 View
  • 200 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We evaluated the prevalence and management of diabetes mellitus (DM) in elderly Korean patients based on data from the Korea National Health and Nutrition Examination Survey (KNHANES).
Methods
A total of 3,068 adults aged 65 years and older (19.8% of total population) were analyzed using KNHANES from 2019 to 2020. Prevalence, awareness, treatment, and control rates, and comorbidities were analyzed. Lifestyle behaviors and energy intake were also measured.
Results
The prevalence of DM and prediabetes was 29.6% and 50.5%, respectively. The awareness, treatment and control rates were 76.4%, 73.3%, and 28.3%, respectively. The control rate was 77.0% if A1C <7.5% criteria was used. The mean A1C value of individuals with known DM was 7.1%, and 14.5% of the known DM patients had A1C ≥8.0%. Abdominal obesity, hypertension, and hypercholesterolemia were combined with DM in 63.9%, 71.7%, and 70.7%, respectively, and the rate of integrated management was 36.0% (A1C <7.5% criteria). A total of 40.1% of those with DM walked regularly. The percentage of energy intake from carbohydrates was higher in those with DM than in those without DM (P=0.044), while those of fat (P=0.003) and protein (P=0.025) were lower in those with DM than in those without DM in women.
Conclusion
In 2019 to 2020, three of 10 adults aged 65 years and older in Korea had DM, and approximately 70% of them had comorbidities. A strategy for more individualized comprehensive care for the elderly patients with DM is urgently needed.

Citations

Citations to this article as recorded by  
  • Association Between High Blood Folate Levels and Glaucoma in a Representative Korean Population
    Ji Young Lee, Jin A. Choi, Sung Pyo Park, Donghyun Jee
    Investigative Opthalmology & Visual Science.2024; 65(1): 6.     CrossRef
  • The Growing Challenge of Diabetes Management in an Aging Society
    Seung-Hwan Lee
    Diabetes & Metabolism Journal.2023; 47(5): 630.     CrossRef
Technology/Device
Glucose Profiles Assessed by Intermittently Scanned Continuous Glucose Monitoring System during the Perioperative Period of Metabolic Surgery
Kyuho Kim, Sung Hee Choi, Hak Chul Jang, Young Suk Park, Tae Jung Oh
Diabetes Metab J. 2022;46(5):713-721.   Published online January 24, 2022
DOI: https://doi.org/10.4093/dmj.2021.0164
  • 4,695 View
  • 316 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Continuous glucose monitoring (CGM) has been widely used in the management of diabetes. However, the usefulness and detailed data during perioperative status were not well studied. In this study, we described the immediate changes of glucose profiles after metabolic surgery using intermittently scanned CGM (isCGM) in individuals with type 2 diabetes mellitus (T2DM).
Methods
This was a prospective, single-center, single-arm study including 20 participants with T2DM. The isCGM (FreeStyle Libre CGM) implantation was performed within 2 weeks before surgery. We compared CGM metrics of 3 days before surgery and 3 days after surgery, and performed the correlation analyses with clinical variables.
Results
The mean glucose significantly decreased after surgery (147.0±40.4 to 95.5±17.1 mg/dL, P<0.001). Time in range (TIR; 70 to 180 mg/dL) did not significantly change after surgery in total. However, it was significantly increased in a subgroup of individuals with glycosylated hemoglobin (HbA1c) ≥8.0%. Time above range (>250 or 180 mg/dL) was significantly decreased in total. In contrast, time below range (<70 or 54 mg/dL) was significantly increased in total and especially in a subgroup of individuals with HbA1c <8.0% after surgery. The coefficient of variation significantly decreased after surgery. Higher baseline HbA1c was correlated with greater improvement in TIR (rho=0.607, P=0.005).
Conclusion
The isCGM identified improvement of mean glucose and glycemic variability, and increase of hypoglycemia after metabolic surgery, but TIR was not significantly changed after surgery. We detected an increase of TIR only in individuals with HbA1c ≥8.0%.

Citations

Citations to this article as recorded by  
  • Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
    Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
    Diabetes & Metabolism Journal.2024; 48(2): 312.     CrossRef
  • Use of Continuous Glucose Monitoring in Patients Following Bariatric Surgery: A Scoping Review
    Yang Yu, Susan W. Groth
    Obesity Surgery.2023; 33(8): 2573.     CrossRef
  • Asymptomatic Hypoglycemia after Metabolic Surgery: New Insights from Perioperative Continuous Glucose Monitoring
    Sang-Man Jin
    Diabetes & Metabolism Journal.2022; 46(5): 675.     CrossRef
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes Metab J. 2022;46(5):817-818.   Published online September 19, 2022
DOI: https://doi.org/10.4093/dmj.2022.0295
Corrects: Diabetes Metab J 2022;46(4):517
  • 1,999 View
  • 141 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review
    Xiang Chen, Li-Hua Li
    Cureus.2023;[Epub]     CrossRef
Drug/Regimen
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes Metab J. 2022;46(4):517-532.   Published online July 27, 2022
DOI: https://doi.org/10.4093/dmj.2022.0198
Correction in: Diabetes Metab J 2022;46(5):817
  • 9,668 View
  • 854 Download
  • 25 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   ePub   
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.

Citations

Citations to this article as recorded by  
  • The role of adherence in patients with chronic diseases
    Michel Burnier
    European Journal of Internal Medicine.2024; 119: 1.     CrossRef
  • Bempedoic acid: new evidence and recommendations on use
    Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
    Current Opinion in Lipidology.2024; 35(1): 41.     CrossRef
  • Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
    Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
    Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
    Journal of Cardiovascular Development and Disease.2024; 11(3): 72.     CrossRef
  • Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
    Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Heliyon.2024; : e28837.     CrossRef
  • Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
    Beibei Hou, Linhui Qin, Linfeng Huang
    Biochemical and Biophysical Research Communications.2023; 644: 85.     CrossRef
  • Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
    C. M. Schooling, J. V. Zhao
    Current Cardiology Reports.2023; 25(2): 67.     CrossRef
  • Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
    Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
    Food Science & Nutrition.2023; 11(6): 2620.     CrossRef
  • Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
    Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206.     CrossRef
  • Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
    Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
    Journal of the American Heart Association.2023;[Epub]     CrossRef
  • The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
    Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Remnant cholesterol, vascular risk, and prevention of atherosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
    Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206.     CrossRef
  • Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
    Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
    Pharmacy.2023; 11(4): 130.     CrossRef
  • Advances in Treatment of Dyslipidemia
    Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
    International Journal of Molecular Sciences.2023; 24(17): 13288.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
    Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
    Scientific Reports.2023;[Epub]     CrossRef
  • Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
    Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
    Current Oncology.2023; 30(9): 8386.     CrossRef
  • Riesgo residual. Conclusiones
    Ángel Cequier, José Luis Zamorano
    Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
  • Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
    Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
    Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
  • Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
    Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
    Biology.2022; 11(9): 1308.     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
Kyuho Kim, Sung Hee Choi
Diabetes Metab J. 2021;45(4):502-504.   Published online July 30, 2021
DOI: https://doi.org/10.4093/dmj.2021.0158
  • 3,328 View
  • 179 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • The neuroprotective potential of phytochemicals in traumatic brain injury: mechanistic insights and pharmacological implications
    Gulam Mustafa Hasan, Saleha Anwar, Anas Shamsi, Sukhwinder Singh Sohal, Md. Imtaiyaz Hassan
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide-Cohort Study (Diabetes Metab J 2020;44:737-46)
Kyuho Kim, Tae Jung Oh
Diabetes Metab J. 2020;44(6):938-939.   Published online December 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0236
  • 3,588 View
  • 73 Download
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Increased Age of Death and Change in Causes of Death Among Persons With Diabetes Mellitus From the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    SSRN Electronic Journal .2020;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal